H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $49 from $43 and keeps a Buy rating on the shares. Acoramidis received regulatory approval with the label underscoring cardiovascular hospitalization and mortality reduction benefits, the analyst tells investors in a research note.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BBIO:
- BridgeBio announces FDA approved Attruby for ATTR-CM patients
- BridgeBio Pharma trading halted, news pending
- BridgeBio Pharma call volume above normal and directionally bullish
- BridgeBio reports open-label extension data on acoramidis in ATTR-CM
- BridgeBio announces publication of PROPEL 2 data in NEJM
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
